Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies

The potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the immunogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Capone, Fioravante, Lucchini, Matteo, Ferraro, Elisabetta, Bianco, Assunta, Rossi, Mariagrazia, Cicia, Alessandra, Cortese, Antonio, Cruciani, Alessandro, De Arcangelis, Valeria, De Giglio, Laura, Motolese, Francesco, Sancetta, Biagio, Mirabella, Massimiliano, Di Lazzaro, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639214/
https://www.ncbi.nlm.nih.gov/pubmed/34859382
http://dx.doi.org/10.1007/s13311-021-01165-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639214/
https://www.ncbi.nlm.nih.gov/pubmed/34859382
http://dx.doi.org/10.1007/s13311-021-01165-9

Ejemplares similares